KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Potent P2Y12 Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy.

Caio A M Tavares, Patricia O Guimarães, Marcelo Franken, José Mariani Junior, Stefano Lemos, Breno O Almeida, Eduardo B Martins, Estêvão L Figueiredo, Aloísio M da Rocha, Alexandre A Soares, Marcos A Marino, Bruno Paolino, Mayler Olombrada Santos, Paulo R A Caramori, Rodrigo M Joaquim, Edgard F Quintella, André F Antonangelo, Alberto G T Fonseca, Marcos S Silveira, Milena R da Fonseca, Frederico Monfardini, Silvia R L Assis, Leonardo R Costa, José C Nicolau, Andrei C Sposito, Renato D Lopes, Yoshinobu Onuma, Marco Valgimigli, Dominick J Angiolillo, Patrick W J C Serruys, Otavio Berwanger, Raul D Santos, Fernando Bacal, Pedro A Lemos, NEO-MINDSET Trial Investigators

J Am Coll Cardiol 87(3) 297-308

PMID41384891
PMCID-
DOI10.1016/j.jacc.2025.10.058
发表日期2025-12-12
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: The effects of very early aspirin withdrawal with potent P2Y12 inhibitor monotherapy after percutaneous coronary intervention may differ based on acute coronary syndrome (ACS) presentation. OBJECTIVES: This prespecified analysis from the NEO-MINDSET trial evaluated whether treatment effects of early aspirin discontinuation differ between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS; defined as unstable angina or non-ST-segment elevation myocardial infarction). METHODS: NEO-MINDSET randomized ACS patients to potent P2Y12 inhibitor monotherapy initiated within 4 days of hospitalization vs standard dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor for 12 months. Co-primary outcomes were: 1) the composite of all-cause death, myocardial infarction, stroke, and urgent target vessel revascularization (ischemic outcome); and 2) Bleeding Academic Research Consortium types 2, 3, or 5 bleeding (bleeding outcome). RESULTS: Of the 3,410 participants included, 2,119 (62.1%) presented with STEMI and 1,291 (37.9%) with NSTE-ACS. Among STEMI patients, an early aspirin-free strategy was associated with a higher rate of the co-primary ischemic composite outcome compared with DAPT at 1 year (8.2% vs 5.2%, respectively; HR: 1.60; 95% CI: 1.14-2.24), whereas among those with NSTE-ACS, ischemic event rates were similar between monotherapy and DAPT (5.1% vs 6.0%, respectively; HR: 0.84; 95% CI: 0.53-1.35; P for interaction = 0.030). The co-primary bleeding outcome was lower with monotherapy than with DAPT in both STEMI (HR: 0.37; 95% CI: 0.22-0.61) and NSTE-ACS (HR: 0.45; 95% CI: 0.23-0.86) populations (P for interaction = 0.650). CONCLUSIONS: In patients with STEMI treated with percutaneous coronary intervention, early aspirin withdrawal may be harmful, because it increases the risk of ischemic events. Conversely, in NSTE-ACS, potent P2Y12 inhibitor monotherapy may be a viable therapeutic option: Ischemic event rates were similar and bleeding was reduced compared with DAPT. (Percutaneous Coronary Intervention Followed by Antiplatelet Monotherapy in the Setting of Acute Coronary Syndromes [NEOMINDSET]; NCT04360720).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。